var data={"title":"Nitrofurantoin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitrofurantoin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6661?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitrofurantoin-drug-information\" class=\"drug drug_general\">see &quot;Nitrofurantoin: Drug information&quot;</a> and <a href=\"topic.htm?path=nitrofurantoin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitrofurantoin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202007\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Furadantin;</li>\n      <li>Macrobid;</li>\n      <li>Macrodantin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202008\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Macrobid;</li>\n      <li>Macrodantin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048970\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048962\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=nitrofurantoin-drug-information\" class=\"drug drug_general\">see &quot;Nitrofurantoin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection (UTI), treatment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Furadantin, Macrodantin: Infants, Children, and Adolescents: Oral: 5 to 7 mg/kg/day divided every 6 hours for 7 days or at least 3 days after obtaining sterile urine; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing: Furadantin oral suspension: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">7 to &lt;12 kg: 12.5 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">12 to &lt; 22 kg: 25 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">22 to &lt;31 kg: 37.5 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">31 to &lt;42 kg: 50 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;42 kg: 50 to 100 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Macrobid (macrocrystal/monohydrate): Adolescents: Oral: 100 mg every 12 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>UTI, prophylaxis:</b> Furadantin, Macrodantin: Infants, Children, and Adolescents: Oral: 1 to 2 mg/kg/day in a single dose (at bedtime) or divided twice daily; maximum daily dose: 100 mg/<b>day</b>. <b>Note:</b> In infants and children &lt;24 months, prophylaxis should only be considered for those with grade III-V reflux or with recurrent febrile UTI; data supporting the routine use of continuous antimicrobial prophylaxis is limited (AAP 2016; AAP [Finnell 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>UTI treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Furadantin, Macrodantin: Oral: 50 to 100 mg every 6 hours; administer for 7 days or at least 3 days after obtaining sterile urine</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Macrobid: Oral: 100 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>UTI prophylaxis:</b> Furadantin, Macrodantin: Oral: 50 to 100 mg at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants &ge;1 month, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;60 mL/minute: Use is contraindicated. <b>Note:</b> Although more evidence is needed, limited data suggest clinicians may consider use in adult patients with CrCl &ge;40 mL/minute when treatment is short term (&le;1 week) for an uncomplicated UTI (Oplinger 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling. Contraindicated in patients with a previous history of cholestatic jaundice or hepatic dysfunction associated with nitrofurantoin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201981\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as macrocrystals: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Macrodantin: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Macrodantin: 50 mg, 100 mg [contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as monohydrate/macrocrystals: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Macrobid: 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Furadantin: 25 mg/5 mL (230 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/5 mL (230 mL, 240 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201965\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048974\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food or milk; do not administer with antacid preparations containing magnesium trisilicate; suspension may be mixed with water, milk, fruit juice, or infant formula. Shake suspension well before use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202001\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Store at controlled room temperature, 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Dispense in a tight container using a child-resistant closure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Avoid exposure to strong light, which may darken the drug. It is stable when stored between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F). Protect from freezing. Dispense in glass amber bottles.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048973\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment and long-term suppression (prevention) of urinary tract infection (UTI) caused by susceptible organisms (Furadantin, Macrodantin: FDA approved in ages &ge;1 month and adults); treatment of acute uncomplicated UTI caused by susceptible strains (Macrobid:  FDA approved in ages &gt;12 years and adults)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3245417\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound alike/look alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Macrobid may be confused with microK, Nitro-Bid</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitrofurantoin may be confused with Neurontin, nitroglycerin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Nitrofurantoin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potential for pulmonary toxicity, hepatotoxicity and peripheral neuropathy, particularly when given long-term; safer alternatives exist. Avoid use in patients with a CrCl less than 30 mL/minute or for long-term suppressive therapy (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Nitrofurantoin (when cumulative day supply is greater than 90 days) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202055\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: ECG changes (nonspecific ST/T wave changes, bundle branch block) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Bulging fontanel (infants), chills, confusion, depression, dizziness, drowsiness, headache, malaise, numbness, paresthesia, peripheral neuropathy, pseudotumor cerebri, psychotic reaction, vertigo </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia, erythema multiforme, exfoliative dermatitis, pruritus, skin rash (eczematous, erythematous, maculopapular), Stevens-Johnson syndrome, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperphosphatemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, <i>Clostridium difficile</i> associated diarrhea, constipation, diarrhea, dyspepsia, flatulence, nausea, pancreatitis, pseudomembranous colitis, sialadenitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urine discoloration (brown)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, eosinophilia, glucose-6-phosphate dehydrogenase deficiency anemia, granulocytopenia, hemoglobin decreased, hemolytic anemia, leukopenia, megaloblastic anemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice, hepatitis, hepatic necrosis, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity (including acute pulmonary hypersensitivity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Superinfection (eg, <i>Pseudomonas</i> or <i>Candida</i>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, lupus-like syndrome, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Amblyopia, nystagmus, optic neuritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Acute pulmonary reaction (symptoms include chills, chest pain, cough, dyspnea, fever, and eosinophilia), cough, cyanosis, dyspnea, pneumonitis, pulmonary fibrosis (with long-term use), pulmonary infiltration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Hepatotoxicty (idiosyncratic) (Chalasani, 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201988\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anuria, oliguria, or significant impairment of renal function (creatinine clearance [CrCl] &lt;60 mL/minute or clinically significant elevated serum creatinine); previous history of cholestatic jaundice or hepatic dysfunction associated with prior nitrofurantoin use; hypersensitivity to drug or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The manufacturer&rsquo;s contraindication in patients with CrCl &lt;60 mL/minute has been challenged in the literature; limited data suggest that an alternative creatinine clearance threshold may be considered (Oplinger, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Because of the possibility of hemolytic anemia caused by immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38 to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent; also contraindicated in neonates younger than 1 month of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201969\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic reactions: Rare, but severe and sometimes fatal hepatic reactions (eg, cholestatic jaundice, hepatitis, hepatic necrosis) have been associated with use (onset may be insidious); discontinue immediately if hepatitis occurs. Monitor liver function tests periodically. Use is contraindicated in patients with a history of nitrofurantoin associated cholestatic jaundice or hepatic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optic neuritis: Postmarketing cases of optic neuritis have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Has been associated with peripheral neuropathy (rare); risk may be increased in patients with anemia, renal impairment (CrCl &lt;60 mL/minute), diabetes, vitamin B deficiency, debilitating disease, or electrolyte imbalance; use caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Acute, subacute, or chronic (usually after 6 months of therapy) pulmonary reactions (possibly fatal) have been observed; if these occur, discontinue therapy immediately. Monitor closely for malaise, dyspnea, cough, fever, radiologic evidence of diffuse interstitial pneumonitis or fibrosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: Use caution in patients with G6PD deficiency; may be at increased risk for hemolytic anemia. Discontinue therapy if occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Urinary nitrofurantoin concentrations are variable in patients with impaired renal function. The manufacturer contraindicates use in CrCl &lt;60 mL/minute; however, limited data suggest nitrofurantoin is safe and effective for short-term treatment of uncomplicated UTI in patients with CrCl 30 to 60 mL/minute (Oplinger 2013; Santos 2016; Singh 2015). The Beers Criteria recommends avoiding use in geriatric patients &ge;65 years with a CrCl &lt;30 mL/minute (Beers Criteria [AGS 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use in elderly patients, particularly females receiving long-term prophylaxis for recurrent UTIs, has also been associated with an increased risk of hepatic toxicity and peripheral neuropathy. Monitor closely for toxicities during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use is contraindicated in children &lt;1 month of age (at increased risk for hemolytic anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Pyelonephritis: Not indicated for the treatment of pyelonephritis or perinephric abscesses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26018452\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Nitrofurantoin should not be used to treat UTIs in febrile infants and young children; nitrofurantoin concentrates in the urine and does not reach therapeutic serum and possibly parenchymal concentrations making it ineffective to treat pyelonephritis or urosepsis (AAP 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299767\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201974\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12645&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Nitrofurantoin may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Trisilicate: May decrease the serum concentration of Nitrofurantoin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norfloxacin: Nitrofurantoin may diminish the therapeutic effect of Norfloxacin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Nitrofurantoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: Nitrofurantoin may enhance the hyperkalemic effect of Spironolactone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202002\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Nitrofurantoin serum concentrations may be increased if taken with food. Management: Administer with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201977\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (contraindicated at term) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201991\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies. Nitrofurantoin crosses the placenta (Perry 1967) and maternal serum concentrations may be lower in pregnancy (Philipson 1979). Current studies evaluating maternal use of nitrofurantoin during pregnancy and the development of birth defects have had mixed results (ACOG 2011). An increased risk of neonatal jaundice was observed following maternal nitrofurantoin use during the last 30 days of pregnancy (Nordeng 2013). Nitrofurantoin may be used to treat infections in pregnant women; use during the first trimester should be limited to situations where no alternative therapies are available. Prescriptions should be written when clinically appropriate and for the shortest effective duration for confirmed infections (ACOG 2011). Nitrofurantoin is contraindicated in pregnant patients at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent due to the possibility of hemolytic anemia in the neonate. Alternative antibiotics should be considered in pregnant women with G-6-PD deficiency (Nordeng 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048969\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of pulmonary reaction; signs of numbness or tingling of the extremities; periodic liver and renal function tests; CBC; urine culture and in vitro susceptibility tests. Observe for change in bowel frequency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201968\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or alter bacterial ribosomal proteins leading to inhibition of protein synthesis, aerobic energy metabolism, DNA, RNA, and cell wall synthesis. Nitrofurantoin is bactericidal in urine at therapeutic doses. The broad-based nature of this mode of action may explain the lack of acquired bacterial resistance to nitrofurantoin, as the necessary multiple and simultaneous mutations of the target macromolecules would likely be lethal to the bacteria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201987\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed; macrocrystalline form absorbed more slowly due to slower dissolution (causes less GI distress) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 60% to 90% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Body tissues (except plasma) metabolize 60% of drug to inactive metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Increased with food by ~40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 20-60 minutes; prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suspension: Urine (~40%) and feces (small amounts) as metabolites and unchanged drug </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Macrocrystals: Urine (20% to 25% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201990\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Macrobid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $693.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Macrodantin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $1,406.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $315.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $661.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Nitrofurantoin Macrocrystal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $703.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $222.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $338.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Nitrofurantoin Monohyd Macro Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $353.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Furadantin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (230 mL): $1,424.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Nitrofurantoin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (230 mL): $730.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201993\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Colifuran (QA);</li>\n      <li>Furadantin (AT, BB, IE, IN, IS, MT, NO, SE, SI);</li>\n      <li>Furadantin Retard (CH);</li>\n      <li>Furadantina (AR, CL, MX);</li>\n      <li>Furadantine (FR, LU);</li>\n      <li>Furadantine MC (BE);</li>\n      <li>Furadantine-MC (NL, PT);</li>\n      <li>Furadin (PK);</li>\n      <li>Furadina (VE);</li>\n      <li>Furadonin (UA);</li>\n      <li>Furadonins (LT, LV);</li>\n      <li>Furanpur (UY);</li>\n      <li>Furantoina (ES);</li>\n      <li>Furitex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Furolin (GR);</li>\n      <li>Macrobid (GB, IE);</li>\n      <li>Macrodantin (AU, BB, CY, EG, IE, IL, IT, MT, PH, QA, TR, ZA);</li>\n      <li>Macrodantina (BR, CL, CO, CR, DO, GT, HN, MX, NI, PA, PE, SV);</li>\n      <li>Macrodantina XR (EC);</li>\n      <li>Macrodin (CY);</li>\n      <li>Macrofuran (ID);</li>\n      <li>Nifuran (NZ);</li>\n      <li>Nifurantin (CZ);</li>\n      <li>Nifuryl (EC);</li>\n      <li>Nifutoin (TW);</li>\n      <li>Nintoin (BD);</li>\n      <li>Ninur (HR);</li>\n      <li>Nitrofurantoin &rdquo;Dak&rdquo; (DK);</li>\n      <li>Nitrofurantoin-ratiopharm (LU);</li>\n      <li>Orafuran (BG);</li>\n      <li>Piyeloseptyl (TR);</li>\n      <li>Rantoin (BD);</li>\n      <li>Siraliden (PL);</li>\n      <li>Urantoin (EC);</li>\n      <li>Uro-Tablinen (DE);</li>\n      <li>Urobak (BD);</li>\n      <li>Urocure (BD);</li>\n      <li>Urofuran (FI);</li>\n      <li>Uroin (KR);</li>\n      <li>Urontin (PH);</li>\n      <li>Urotoina (PY);</li>\n      <li>Uvamin (CR, DO, GT, HN, IL, NI, PA, SV);</li>\n      <li>Uvamin Retard (AE, CH, EG, KW, LB, LV, QA, SA, TT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP) Subcommittee on urinary tract infection. Reaffirmation of AAP Clinical Practice Guideline: the diagnosis and management of the initial urinary tract infection in febrile infants and young children 2-24 months of age. <i>Pediatrics</i>. 2016;138(6).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/27940735/pubmed\" target=\"_blank\" id=\"27940735\">27940735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/21873693 /pubmed\" target=\"_blank\" id=\"21873693 \">21873693 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 494: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1484-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/21606771/pubmed\" target=\"_blank\" id=\"21606771\">21606771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brendstrup L, Hjelt K, Petersen KE, et al, &ldquo;Nitrofurantoin Versus Trimethoprim Prophylaxis in Recurrent Urinary Tract Infections in Children,&rdquo; <i>Acta Paediatr Scand</i>, 1990. 79(12):1225-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/2085111/pubmed\" target=\"_blank\" id=\"2085111\">2085111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coraggio MJ, Gross TP, and Roscelli JD, &ldquo;Nitrofurantoin Toxicity in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1989, 8(3):163-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/2652087/pubmed\" target=\"_blank\" id=\"2652087\">2652087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finnell SM, Carroll AE, Downs SM, Subcommittee on Urinary Tract Infection. Technical report&mdash;diagnosis and management of an initial UTI in febrile infants and young children. <i>Pediatrics</i>. 2011;128(3):e749-e770.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/21873694/pubmed\" target=\"_blank\" id=\"21873694\">21873694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furadantin oral suspension (nitrofurantoin) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals, Inc; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-13999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/8498418 /pubmed\" target=\"_blank\" id=\"8498418 \">8498418 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macrobid capsules (nitrofurantoin) [prescribing information]. Pine Brook, NJ: Almatica Pharma, Inc; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macrodantin capsules (nitrofurantoin) [prescribing information]. Pine Brook, NJ: Almatica Pharma, Inc; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nordeng H, Lupattelli A, Rom&oslash;ren M, et al. Neonatal outcomes after gestational exposure to nitrofurantoin. <i>Obstet Gynecol</i>. 2013;121(2 Pt 1):306-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/23344280 /pubmed\" target=\"_blank\" id=\"23344280 \">23344280 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23341159\"></a>Oplinger M and Andrews CO. &ldquo;Drug Information Rounds: Nitrofurantoin Contraindication in Patients With a Creatinine Clearance Below 60 mL/min: Looking for the Evidence,&rdquo; <i>Ann Pharmacother</i>, 2013, 47(1):106-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/23341159/pubmed\" target=\"_blank\" id=\"23341159\">23341159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry JE and Leblanc AL, &quot;Transfer of Nitrofurantoin Across the Human Placenta,&quot; <i>Tex Rep Biol Med</i>, 1967a, 25(2):265-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/6068160/pubmed\" target=\"_blank\" id=\"6068160\">6068160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A. Pharmacokinetics of antibiotics in pregnancy and labour. <i>Clin Pharmacokinet</i>. 1979;4(4):297-309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/385210 /pubmed\" target=\"_blank\" id=\"385210 \">385210 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pons G, Rey E, Richard MO, et al. Nitrofurantoin excretion in human milk. <i>Dev Pharmacol Ther</i>. 1990;14(3):148-152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/2364853/pubmed\" target=\"_blank\" id=\"2364853\">2364853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos JM, Batech M, Pelter MA, et al. Evaluation of the risk of nitrofurantoin lung injury and its efficacy in diminished kidney function in older adults in a large integrated healthcare system: a matched cohort study. <i>J Am Ger Soc.</i> 2016;64:798-805.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/27100576 /pubmed\" target=\"_blank\" id=\"27100576 \">27100576 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh N, Gandhi S, McArthur E, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. <i>Can Med Assoc J. </i>2015; 187(9):648-656.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/25918178 /pubmed\" target=\"_blank\" id=\"25918178 \">25918178 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zao J, Koren G, Bozzo P. Using nitrofurantoin while breastfeeding a newborn. <i>Can Fam Physician</i>. 2014;60(6):539-540.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/24925943/pubmed\" target=\"_blank\" id=\"24925943\">24925943</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12645 Version 175.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202007\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F202008\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048970\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048962\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201981\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F201965\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048974\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F202001\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048973\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3245417\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F202055\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201988\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201969\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26018452\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299767\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201974\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F202002\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F201977\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F201991\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048969\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201968\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F201987\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F201990\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F201993\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12645|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitrofurantoin-drug-information\" class=\"drug drug_general\">Nitrofurantoin: Drug information</a></li><li><a href=\"topic.htm?path=nitrofurantoin-patient-drug-information\" class=\"drug drug_patient\">Nitrofurantoin: Patient drug information</a></li></ul></div></div>","javascript":null}